To study the effect that hydroxypropylcellulose (HPC) polymer molecular weight (MW) exerts on drug release rates and mechanism from matrix tablets.

Similar documents
Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig

PHARMACEUTICAL TECHNOLOGY REPORT. Abstract Summary. Introduction. Experimental Methods. Consumer Specialties ashland.com

Table 1 Hydrophilicity of MC and HPMC Grades. Polymer Cloud Point ( C) Hydrophilicity MC HPMC Type 2910 HPMC Type

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

Evaluation of different binders for roller compaction R. Wang, W. Liu, T. Durig

Evaluation of Moisture Sorption Methods for Aqueous Moisture Barrier Coatings D. Tewari, R. Lewis, B. Kinsey and T. Dürig*

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

Pharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency

DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa, NJ

FORMULATION AND EVALUATION OF THEOPHYLLINE BILAYERED TABLETS USING HPC AS MATRIX MATERIAL

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies

Klucel hydroxypropylcellulose. Physical and chemical properties

Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1

Dow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

we ve got you covered pharmaceutical product and solution guide

The unlocked synergy of DFE Pharma MCC

SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING

SENTRY TM POLYOX Water Soluble Resins

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations

Adopting Technologies to Enhance Quality in Manufacturing

CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION

Critical material properties for the design of robust drug products : excipient functionality related characteristics

A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac

Dextrol and Strodex Surfactant Selection Guide

FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD

Volume: 2: Issue-3: July-Sept ISSN FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL

DEVELOPMENT AND IN VITRO EVALUATION OF SUSTAINED RELEASE FLOATING MATRIX TABLETS OF METFORMIN HYDROCHLORIDE

Journal of Chemical and Pharmaceutical Research

Continuous Granulation Using a Twin-Screw Extruder. Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants?

PREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE VEHICLE IN TABLET FORMULATIONS

Comparative Evaluation of Enteric Film Coatings Applied in Organic Solvents

Re-compaction properties of lactose and microcrystalline cellulose

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

PHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS

EUDRAGIT L 100 and EUDRAGIT S 100

METOLOSE: CONTENTS PAGE

OPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105

Development and Evaluation of Press Coated Tablet of Aceclofenac Shinde PV* and Mayee RV

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

Formulation and Development of Sustained Release Tablets of Valsartan Sodium

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant

Soluplus The Solid Solution Opening New Doors in Solubilization.

Easy, fast and reliable!

Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media

Water-free Anionic Surfactants

3. Drug or plant or excipients profile

FLORITER. New Technology for Innovative Formulation Design.

ENHANCEMENT OF SOLUBILITY OF BICALUTAMIDE DRUG USING SOLID DISPERSION TECHNIQUE

Patel Krunal M et al. IRJP 2 (2)

EUDRAGIT E 100, EUDRAGIT E PO and

Biopharmaceutics Dosage form factors influencing bioavailability Lec:5

STARCH Application Data

4. Monitoring of dissolution induced changes in film coat

Opadry Enteric. Application Data. Drug Release from Acrylic-Based Opadry Enteric (94 Series) Coated Tablets INTRODUCTION MATERIALS AND METHODS

A FACTORIAL STUDY ON THE ENHANCEMENT OF DISSOLUTION RATE OF KETOPROFEN BY SOLID DISPERSION IN COMBINED CARRIERS

1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

Asian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012

EVALUATION OF EFFERVESCENT FLOATING TABLETS. 6.7 Mathematical model fitting of obtained drug release data

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical

A study of compressibility and compactibility of directly compressible tableting materials containing tramadol hydrochloride

Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or

Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS

Journal of Chemical and Pharmaceutical Research

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

PREPARATION AND INVITRO EVALUATION OF RABEPRAZOLE SODIUM DELAYED RELEASE ENTERIC COATED TABLETS

International Journal of Research in Pharmacy and Science

Available Online through Research Article

Folic Acid in Human Nutrition

Sivakasi , Tamil Nadu, India. ABSTRACT KEYWORDS:

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices

Transdermal Delivery of Newer Atypical Antipsychotics ABSTRACT

Easy, fast and reliable!

(12) Patent Application Publication (10) Pub. No.: US 2003/ A1

Formulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch

In-Vitro Bioequivalence Studies for Oral Solid Dose products using the Morphologi G3-ID

Eastman cellulose esters Pharmaceutical applications and drug delivery

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

Permeability Study on Cellulose Acetate Butyrate Coating Film

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels

Formulation development of Glipizide matrix tablet using different proportion of natural and semi synthetic polymers

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2010/39

Int. Res J Pharm. App Sci., 2014; 4(1):47-51 ISSN:

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Kollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M. Super-disintegrants and dissolution enhancers.

Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets

REVISION OF MONOGRAPH ON TABLETS. Tablets

Preparation and Evaluation of Silymarin Controlled Release Tablets Prepared Using Natural Gums

Non-Food Uses of Polysaccharides

International Journal of Medicine and Pharmaceutical Research

Release Modification of Indomethacin Controlled Release Press Coated Tablets

Bioavailability enhancement of poorly soluble APIs. Enhanced solubilization out of solid glassy solutions prepared by Hot-Melt Extrusion

with Diltiazem Hydrochloride

Transcription:

PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-029-1 (Supersedes PTR 029) Page 1 of 7 Hydroxypropylcellulose in Modified Release Matrix Systems: Polymer Molecular Weight Controls Drug Release Rate and Mechanism T. Dürig, K. M. Lusvardi and W. W. Harcum Objective To study the effect that hydroxypropylcellulose (HPC) polymer molecular weight (MW) exerts on drug release rates and mechanism from matrix tablets. Introduction Hydroxypropylcellulose (HPC) is a versatile nonionic cellulose ether, combining dual solubility in water and polar organic solvents with high surface activity and true thermoplasticity. In the formulation of modified release matrix systems, HPC is well known for its efficiency in controlled release (1-3) and its outstanding compactibility (4). Fine particle size HPC grades are of particular importance as reduction in particle size can reduce drug release rates (1, 2). This effect has been attributed to a more rapid rate of hydration, leading to more rapid formation of the diffusion-controlling gel layer around the dry tablet core. Finer particle size also significantly increases HPC tablet compactibility and binder efficiency (5). Fine particle size HPC has traditionally been available as high and low molecular weight (MW) grades designated as Klucel Pharm hydroxypropylcellulose, grades HXF and EXF, with typical mean particle size between 80 and 100 µm. This study evaluates the importance of HPC MW in modified release. For this purpose, three new fine particle grades of Klucel Pharm HPC were developed with intermediate MW. These grades are designated as MXF, GXF and JXF. The grades of fine particle size HPC polymer used in these studies are detailed below. Klucel Pharm HPC Grade Nominal Molecular Weight (kda) Apparent Viscosity (mpa s) EXF 80 300-600 at 10% JXF (new) 140 150-400 at 5% GXF (new) 370 150-400 at 2% MXF (new) 850 4000-6500 at 2% HXF 1150 1500-3000 at 1% Model formulations comprising a BCS Class I soluble drug (theophylline) and a BCS Class II insoluble drug (nifedipine) were used. Additional variables for the theophylline formulations included polymer level (20 and 40%) and an increase in drug load (40%). While a number of reports have been published on MW effects in hypromellose (HPMC) based systems, there is little published data on these aspects with respect to HPC. Note: This work was presented at the Annual Meeting of the American Association of Pharmaceutical Scientists, November 7-11, 2004, Baltimore, Maryland. All statements, information and data presented herein are believed to be accurate and reliable, but are not to be taken as a guarantee, an express warranty, or an implied warranty of merchantability or fitness for a particular purpose, or representation, express or implied, for which Ashland and its subsidiaries assume legal responsibility. Registered trademark, Ashland or its subsidiaries, registered in various countries. Trademark, Ashland or its subsidiaries, registered in various countries. *Trademark owned by a third party. 2011, Ashland. Rev. 11-2011

Page 2 of 7 Procedures Directly compressed nifedipine and theophylline tablets comprising 20% drug, 30% Klucel HPC, 49.5% silicified microcrystalline cellulose (MCC) polymer and 0.5% magnesium stearate were prepared on a Manesty Betapress. Additional theophylline formulations were prepared with varied polymer level (20 and 40%) or increased drug dose (40% theophylline), where the MCC levels were reduced. Theophylline tablet dissolution testing was performed in USP apparatus I in ph 6.8, 0.5M phosphate buffer. For nifedipine, USP apparatus II was modified by placing the tablets on a 7 cm round stainless steel mesh which was located at the bottom of the dissolution flask. This modification was made to prevent poorly soluble tablets or drug particles from accumulating in the stagnant solvent layers at the bottom of the dissolution vessel, as described previously (6). The dissolution medium was ph 4.6 buffer enriched with 1% sodium lauryl sulfate. Tablet erosion and uptake of the dissolution medium uptake were determined gravimetrically in the same conditions as used for dissolution testing. Basic calculations are shown below. Additional experimental details have been described previously (7). Dissolution Medium Uptake (%) = 100 (Wet Weight - Remaining Dry Weight) Remaining Dry Weight Remaining Mass (%) = 100 (Remaining Dry Weight) Original Dry Weight Results Effect of MW on Insoluble Drug Release (Nifedipine) Figure 1 shows that the release rate of 20% nifedipine is effectively regulated by varying the MW of fine particle size HPC. After an initial lag time all profiles are relatively linear, with t40% values ranging from 5 hours for EXF to 20 hours for HXF. The lag times can be attributed to the low wettability and low aqueous solubility of nifedipine, resulting in negligible initial diffusion until steady state conditions have been established. Figure 1 Effect of Fine Particle Klucel HPC MW on Nifedipine Dissolution

Page 3 of 7 Effect of MW Weight on Erosion and Swelling Behavior of Nifedipine Tablets The drug release kinetics largely correlates with the tablet erosion rates and are inversely proportional to the rate of water uptake in this matrix system (Figures 2 and 3). The low and intermediate MW grades, EXF, JXF and GXF, achieve complete tablet erosion within the 24-hour test period. High MW HXF and MXF show limited erosion of 20 and 40%, respectively, over a 24 hour period. The trend of lower erodibility with higher MW coincides with greater swelling tendency as indicated by water uptake rate into the matrix. Confirming the MW dependency of swelling and erosion kinetics, lower MW tablets are significantly smaller in volume after 4 hours of dissolution testing as compared to higher MW grades (Figure 4). For low MW, the tablet surface is rougher and grainier in appearance, allowing visual distinction of white MCC interspersed in the intensely yellow-colored drug blend. Figure 2 Effect of Fine Particle Klucel HPC MW on Nifedipine Tablet Erosion Figure 3 Effect of Fine Particle Klucel HPC MW on Nifedipine Tablet Medium Uptake

Page 4 of 7 Figure 4 Effect of Fine Particle Klucel HPC MW on Erosion and Swelling Behavior Nifedipine Matrix Tablets Subjected to Dissolution Testing for 4 and 8 Hours (Ruler shows 1mm spacing). For insoluble drugs such as nifedipine, drug dissolution rate is the rate limiting factor. In addition to the very limited diffusion of dissolved drug through the tablet matrix, low and medium MW grades promote the liberation of undissolved drug particles by surface erosion. These particles can then dissolve more rapidly in the bulk fluid. In contrast, high MW grades have limited erodibility, but cause a substantial increase in overall tablet volume and gel layer thickness with time. Drug release is therefore primarily due to diffusion of dissolved drug through the gel layer. Due to the solubility constraints, a significant amount of undissolved drug remains trapped in the tablet matrix well beyond 24 hours. A change in release mechanism can therefore be readily achieved by changing the MW of fine particle size HPC in a formulation. The new intermediate fine particle grades of Klucel Pharm HPC can therefore serve as a highly effective tool to control insoluble drug release profiles within physiologically relevant time periods. Effect of Molecular Weight on Soluble Drug Release (Theophylline) Figure 5 shows that varying the MW of fine particle size HPC is also effective in regulating the drug release kinetics for a soluble drug such as theophylline. At a 20% drug load, the achievable release rate variation among the HPC grades for theophylline was lower than the variation found for nifedipine. The t60% values varied from 5.5 hours for EXF to 13 hours for HXF. Noticeably for the higher MW HXF and MXF, a viscosity threshold exists above which further increases in viscosity result in only negligible release duration gains. Similar observations have been made previously for hydroxyethylcellulose and hypromellose (8, 9). As observed for the nifedipine tablets, the lower MW EXF and JXF tablets eroded completely. In contrast, higher MW grades gradually increased in volume due to swelling.

Page 5 of 7 Figure 5 Effect of Fine Particle Klucel HPC MW Variation on Theophylline Dissolution Formulation: 20% Theophylline, 30% HPC, 49.5% MCC, 0.5% Mag Stearate Effect of MW When Soluble Drug Load is Increased The impact of polymer MW variation increases when theophylline drug load is increased from 20 to 40%, with t60% values ranging from 2.5 hours for EXF to 18 hours for HXF and MXF. In addition to faster release, the profiles for low viscosity grades EXF and JXF are also more linear at the higher drug load (Figure 6). For higher MW grades, release decreases as drug load increases. As is typical for diffusion mediated release, profiles remain curved, with release rates declining in the late time period. As observed earlier for nifedipine, the change in MW results in a fundamental shift in release mechanism, with diffusion of drug through the gel layers dominating for high viscosity grades, while drug dissolution and matrix ero- sion are more important at lower MW. Figure 6 Effect of Fine Particle Klucel HPC MW When Drug Load is Increased Formulation: 40% Theophylline, 30% HPC, 29.5% MCC, 0.5% Mag Stearate

Page 6 of 7 Effect of MW on Soluble Drug Release When Polymer Level is Increased The differences in release mechanism are further highlighted when polymer levels are varied from 20 to 30 and 40% HPC. Release rates markedly increase for lower MW EXF and JXF (Figure 7). This can be attributed to the greater solubility and erodibility of lower MW grades, which can be added to a formulation in higher proportions to speed up release. In the case of intermediate MW GXF, changing polymer level has minimal effect indicating a balance between swelling and erosion processes. For higher MW HXF and MXF, there is a slight decrease in release rates as polymer levels are increased, indicating a predominance of swelling mediated diffusion over erosion. Figure 7 Effect of Fine Particle Klucel HPC MW on Theophylline Dissolution Profiles Formulation: 20% Theophylline, 20-40% HPC, 0.5% Mag Stearate, q.s. MCC Conclusions Varying molecular weight (MW) of fine particle HPC over the nominal range of 80 to 1150 kda provides significant and effective control of in vitro drug release rates for both soluble and insoluble drugs. Lower MW HPC types up to ~370 kd undergo significant erosion. For MW above this threshold, diffusion through the swelling gel layer becomes more significant. These grades provide a simple and effective means to vary the release profile and mechanisms and offer the advantage of allowing tablet size, chemical composition and proportion of components to remain constant. The three new grades of fine particle size Klucel HPC provide a valuable addition to the formulation opportunities for controlling modified release matrix systems.

Page 7 of 7 References 1. Johnson, J.L. et. al., Influence of ionic strength on matrix integrity and drug release from hydroxypropylcellulose compacts. Int. J. Pharm.90, 151-159 (1993). 2. Alderman, D.A., US Patent 4,704,285 (11/3/87, expires 11/18/05, contact Dow Chemical for further info). 3. DY Lee, D. Y. and Chen C.M., US Patent 6,103,263, granted 8/15/00, expires 11/17/14. 4. Joneja, S.K. et al, Investigating the fundamental effects of binders on pharmaceutical tablet. Drug Dev Ind Pharm, 25, 1129-35 (1999). 5. Evaluation of Hydroxypropylcellulose as a Direct Compression Binder, Ashland Pharmaceutical Technology Report PTR-025. 6. Dürig, T. and Fassihi, R., Evaluation of Floating and Sticking Extended Release Delivery Systems: An Unconventional Dissolution Test. J. Controlled Release, 67, 37-44, 2000. 7. Dürig, T. and Fassihi, R., Guar-based monolithic matrix systems: effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. J. Controlled Rel., Volume 80(1-3):45-56, 2002. 8. Versatility of Natrosol Hydroxyethylcellulose in Controlled Release Matrix Systems, Ashland Pharmaceutical Technology Report PTR-017. 9. Benecel Hypromellose for Use in Modified Release Drug Dosage Forms: Performance Similarity to Competitive Grades, Aqualon Technical Information Bulletin VC-631. Materials 1. Klucel Pharm hydroxypropylcellulose, grades HXF, MXF, GXF, JXF and EXF, marketed by Ashland Specialty Ingredients, Ashland Inc., Wilmington, DE. 2. Theophylline anhydrous, USP, marketed by BASF Corporation, Mount Olive, NJ. 3. Nifedipine, USP, marketed by Spectrum Corporation, Gardena, CA. 4. ProSolv HD* 90 silicified microcrystalline cellulose, NF, marketed by J. Rettenmaier & Söhne GmbH & Co. KG, Rosenberg, Germany. 5. HyQual* magnesium stearate, NF, marketed by Mallinckrodt Inc., a Division of Tyco International, St. Louis, MO.